Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.6.1.3 (ATPase)
65,361 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Previously, we attributed the binding of F-actin to the 38-residue stretch of gizzard calponin encompassing the sequence A145-Y182 and postulated the hexapeptide motif VKYAEK, representing residues 142-147, as a putative actin-binding site [Mezgueldi, M., Fattoum, A., Derancourt, J. & Kassab, R. (1992) J. Biol. Chem. 267, 15943-15951]. Herein, the nature of the ATPase inhibitory amino acids of calponin and their relative position within the actin binding domain was investigated by expressing the following fragments of mouse calponin with or without substitution or deletion of the hexapeptide V142-K147: amino acids 1-228 (CaP1-228), 45-228 (CaP45-228), 131-228 (CaP131-228), and CaP1-228 with substitution of A145 with S (CaP1-228A145S) or deletion of V142-K147 (CaP1-228de1142-147). All the recombinant fragments displayed most of the biochemical properties of the smooth muscle purified calponin including (a) expected electrophoretic mobility, (b) heat stability, (c) binding to actin, tropomyosin and calmodulin, and (d) zero-length cross-linking to actin switched by calmodulin in a calcium-dependent fashion. However, while the wild-type recombinant fragments inhibit the acto-S-1 ATPase activity to the same extent as do the parent calponin, modulation of the hexapeptide by either substitution or deletion strongly affect the inhibitory activity with only slightly decreasing actin binding capacity. The data indicate that the stretch VKYAEK is crucial for ATPase inhibition by calponin but represents only part of the actin-binding domain. These results are discussed in terms of multiple contact sites between actin and calponin.
...
PMID:Expressing functional domains of mouse calponin: involvement of the region around alanine 145 in the actomyosin ATPase inhibitory activity of calponin. 861 84

Calponin inhibits actin-activated myosin adenosinetriphosphatase (ATPase) activity, and phosphorylation reverses this inhibition. Calponin phosphorylation has been demonstrated in reconstituted contractile protein systems, but studies using intact smooth muscle have produced mixed results. The goal of this study was to determine if vascular smooth muscle contains the necessary biochemical machinery to catalyze calponin phosphorylation. We used swine carotid homogenate, which allows access to the intracellular components and contains all endogenous proteins and enzymes in physiologically relevant concentrations. We demonstrated that calponin is phosphorylated in response to Ca2+ (0.27 +/- 0.04 mol P(i)/mol calponin) and in response to phorbol 12,13-dibutyrate in the presence or absence of Ca2+ (0.48 +/- 0.09 mol P(i)/mol calponin). Calponin phosphorylation was inhibited by the protein kinase C inhibitor staurosporine but not by the Ca(2+)- and calmodulin-dependent protein kinase II inhibitor KN-62. We conclude that Ca(2+)-dependent and -independent isoforms of protein kinase C but not the Ca(2+) -and calmodulin-dependent protein kinase II catalyze calponin phosphorylation in the swine carotid artery.
...
PMID:Calcium-and phorbol ester-dependent calponin phosphorylation in homogenates of swine carotid artery. 877 Jan 22

Calponin, a thin filament-associated protein, inhibits actomyosin adenosinetriphosphatase in solution and has been suggested to modulate smooth muscle contractility. We used permeabilized guinea pig taenia coli smooth muscle to investigate whether calponin can modulate actin-myosin interaction in a more organized contractile system. Fibers were permeabilized with Triton X-100 and glycerol, which permit access of large macromolecules to the contractile apparatus. For contractures elicited by Ca2+ (6.6 microM + 0.1 microM calmodulin), the recombinant alpha-isoform of chicken gizzard calponin (CaP) decreased isometric force (Fo) and unloaded shortening velocity (Vus) in a dose-dependent manner; 1 microM CaP had minimal effects on force (< 10%) but reduced Vus by approximately 50% and 10 microM CaP reduced Fo to 27% of control and Vus to near zero levels. To eliminate any effects of the binding of calmodulin by CaP and consequent inhibition of myosin light chain kinase activity, we also studied fibers activated by thiophosphorylation of the myosin regulatory light chain. Fo was only moderately inhibited, remaining at approximately 75% of control in the presence of CaP (10 microM), whereas Vus was reduced to 32% of control. A similar inhibition was obtained with a mutant (CaPcys175) that retains the ability to bind to actin. CaP phosphorylated by protein kinase C and CaPcys175 mutant labeled with 1,5-IAEDANS, which bind actin poorly, were not effective inhibitors. Our results indicate that 1) CaP more strongly inhibits Vus (approximately cross-bridge cycle rate) than Fo (approximately number of activated cross bridges) and 2) the effects of CaP are related to its binding to actin. Thus the function of CaP in regulation of smooth muscle contractility may be more strongly related to its function as a modulator of velocity, as related to the "latch state," than as an "on-off" switch.
...
PMID:Effects of calponin on isometric force and shortening velocity in permeabilized taenia coli smooth muscle. 877 10

Calponin, an actin/calmodulin-binding protein present in smooth muscle thin filaments, modulates the actin-myosin interaction and actomyosin ATPase activity of smooth muscle myosin II. Binding of myosin heads to actin under conditions that produce weak or strong binding induces conformational changes in actin. Polarized fluorimetric measurements of rhodamine-phalloidin complex and 1,5-IAEDANS specifically linked to actin in myosin-free muscle fibers (ghost fibers) and to Cys-707 in myosin head, respectively, revealed conformational changes, as determined from the changes in orientation and mobility of fluorescent probes, upon addition of calponin to ghost fibers. The effect of calponin on conformational changes produced upon binding of phosphorylated or dephosphorylated heavy meromyosin (HMM) was also determined. Subfragment-1 preparation modified with NEM (NEM-S1) or pPDM (pPDM-S1) were used as models of strong and weak binding, respectively. Calponin changed both the orientation of fluorophores on the actin and the flexibility of the actin filaments, as determined from the angle between an actin filament and the fiber axis. Changes in the flexibility of actin filaments and the orientation of fluorophores produced by phosphorylated smooth muscle HMM were similar to those seen with NEM-S1, which formed a strong-binding association with actin and caused the transition of actin monomers to the "on" state; calponin markedly inhibited this effect. In contrast, pPDM-S1 and dephosphorylated HMM induced weak binding and the transition of actin monomers to the "of" state, and these effects were enhanced by calponin. Furthermore, calponin decreased the velocity of actin filament movement over skeletal muscle myosin O gamma phosphorylated smooth muscle myosin heads in an in vitro motility assay. These results suggest that calponin induces modulation of smooth muscle contraction by inhibiting the force-producing (strong-binding) state of cross-bridges and involves changes in actin conformation.
...
PMID:Modulation of actin conformation and inhibition of actin filament velocity by calponin. 890 28

We have investigated the mechanism of inhibition of the actomyosin MgATPase by the smooth muscle protein calponin. We have shown previously the specific interaction of calponin with Glu334 of actin (EL-Mezgueldi, M., Fattoum, A., Derancourt, J., and Kassab, R. (1992) J. Biol. Chem. 267, 15943-15951). This residue is within the sequence 332-334, which has been proposed to be an important part of the strong myosin binding site (Rayment, I., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M., Holmes, K. C., and Milligan, R. A. (1993) Science 261, 58-65). Therefore, we suggested that calponin will affect the strong binding actin-myosin interaction. To test this hypothesis we have investigated the effect of calponin on the strong binding of S-1.MgAMP-PNP (5'-adenylyl imidodiphosphate) and on the weak binding of S-1.MgADP.Pi to actin. We found that an inhibitory concentration of calponin decreased the binding of S-1. MgAMP-PNP to actin but had no effect on the binding of S-1.MgADP.Pi. Similar results were obtained with skeletal muscle and smooth muscle S-1. In competition experiments calponin was found to displace S-1. MgAMP-PNP and S-1.MgADP but not S-1.MgADP.Pi from the actin filament. S-1 displaced calponin from actin in the rigor state, in the presence of MgADP, and in the presence of MgAMP-PNP. We conclude that calponin inhibits the actin activated S-1 ATPase by blocking a strong S-1 binding site on actin and does not block the weak binding site.
...
PMID:The effects of smooth muscle calponin on the strong and weak myosin binding sites of F-actin. 891 Apr 31

Although the actin-binding and actomyosin adenosinetriphosphatase (ATPase) inhibitory properties of calponin are well documented in vitro, its function in the smooth muscle cell has not been elucidated. To address this question, we utilized the ferret aortic smooth muscle cell, which shows a protein kinase C-dependent contraction even at pCa (-log [Ca2+]) 9.0 in the absence of a change in myosin light chain phosphorylation. Force was recorded from single, briefly permeabilized cells stimulated via a Ca(2+)-independent pathway by either phenylephrine or the epsilon isoenzyme of protein kinase C. Treatment of stimulated cells with wild-type recombinant calponin reduced steady-state contractile force by 45-60%. When calponin application preceded protein kinase C epsilon treatment, contraction was completely suppressed. On the other hand, calponin phosphorylated at Ser175 or mutant calponin with a Ser175 --> Ala replacement had no effect on contractile force. A peptide corresponding to Leu166-Gly194 of calponin, which included an actin-binding domain but excluded the actomyosin ATPase inhibitory region, was synthesized. Treatment of aortic smooth muscle cells with this peptide triggered a concentration-dependent contraction, presumably by alleviating the inhibitory effect of endogenous calponin. A control peptide with a scrambled sequence of the same residues produced no detectable contractile response. Although other interpretations are possible, these results are consistent with the view that calponin participates in thin filament-mediated regulation of smooth muscle contraction and that it may be part of a Ca(2+)-independent pathway downstream of protein kinase C epsilon.
...
PMID:Effects of calponin on force generation by single smooth muscle cells. 892 96

Calponin is a thin-filament-associated protein that has been implicated in the regulation of smooth-muscle contractility. It binds to F-actin and inhibits the MgATPase activity of actomyosin. In the present work we have examined the effect of recombinant chicken gizzard alpha-calponin (R alpha CaP) on the binding of rabbit skeletal-muscle myosin subfragment 1 (S1) to F-actin and on the inhibition of its actin-activated MgATPase. We have found that binding of one R alpha CaP molecule to every three to four actin monomers is sufficient for maximal inhibition of acto-S1 ATPase. At this R alpha CaP/actin ratio R alpha CaP does not interfere with S1 binding to F-actin. At higher concentrations, R alpha CaP displaces S1 from F-actin and a 1:1 R alpha CaP-actin monomer complex is formed. R alpha CaP is also able to displace troponin I from its complex with F-actin which may reflect the amino acid sequence similarity between R alpha CaP and troponin I in their actin-binding regions.
...
PMID:Correlation between calponin and myosin subfragment 1 binding to F-actin and ATPase inhibition. 902 Aug 89

Calponin is a troponin-T like protein purified from chicken gizzard smooth muscle. It binds to actin, myosin, Ca(2+)-binding proteins and tropomyosin and inhibits the actomyosin ATPase as well as the movement of actin filaments over myosin in vitro. These properties have led to the proposal that calponin may be involved in the Ca(2+)-dependent regulation of actin-myosin interaction and consequently of smooth muscle contraction. Calponin is localized in both the contractile and the cytoskeletal parts of the smooth muscle cell and may have a structural function in smooth muscle cells. It may also regulate the pool of free actin available for cytoskeleton organization. In vitro calponin function is modulated by its interaction with a Ca(2+)-binding protein and/or by its phosphorylation. This suggests that calponin may play an important role in signal transduction from the membrane receptor to the contractile proteins in smooth muscle.
...
PMID:Calponin. 902 77

Calponin is a smooth-muscle thin-filament protein implicated in the regulation of contraction. Its binding to actin is a prerequisite for inhibition of actin-activated myosin MgATPase. Investigating the molecular mechanism of this inhibition, it was found that titration of acto-myosin subfragment 1 with calponin in the presence of either ADP or ATP does not displace weakly or strongly bound myosin subfragment 1 (S1) from actin. S1.ADP, however, is able to release about two-thirds of the calponin from saturated (equimolar) complexes of actin-calponin. The remaining calponin is sufficient for almost full inhibition of acto-S1 MgATPase activity. Bunding of actin filaments by calponin takes place at a higher ratio calponin/actin (above 1:3) and, therefore, is not responsible for inhibition of the ATPase. Bundle formation is inhibited by S1.ADP. These results suggest the existence of two calponin-binding sites on actin; one, that is insensitive to S1, which is responsible for inhibition of the ATPase, the other, from which calponin is readily displaced by S1.
...
PMID:Calponin inhibits actin-activated MgATPase of myosin subfragment 1 (S1) without displacing S1 from its binding site on actin. 905 24

Calponin is a putative thin filament regulatory protein of smooth muscle that inhibits actomyosin ATPase in vitro. We have used electron microscopy and three-dimensional reconstruction to elucidate the structural organization of calponin on actin and actin-tropomyosin filaments. Calponin density was clearly delineated in the reconstructions and found to occur peripherally along the long-pitch actin-helix. The main calponin mass was located over sub-domain 2 of actin, and connected axially adjacent actin monomers by binding to the "upper" and "lower" edges of sub-domains 1 of each actin. When the reconstructions were fitted to the atomic model of F-actin, calponin appeared to contact actin near the N terminus and at residues 349 to 352 close to the C terminus of sub-domain 1 on one monomer. It also touched residues 92 to 95 of sub-domain 1 on the axially neighboring actin and continued up the side of this monomer as far as residues 43 to 48 of sub-domain 2. These positions are consensus binding sites for a number of actin-associated proteins and are also near to sites of weak myosin interaction. Calponin did not appear to block strong myosin binding sites on actin. In contrast to the calponin mass which appeared monomeric in reconstructions, tropomyosin formed a continuous strand of added density along F-actin. When added to tropomyosin-containing filaments, calponin caused a shift of tropomyosin away from sub-domain 1 towards sub-domain 3 of actin, exposing strong myosin-binding sites that were previously covered by tropomyosin. This structural effect is unlike that of troponin and therefore inhibition of actomyosin ATPase by calponin and troponin cannot be strictly analogous. The location of calponin would allow it to directly compete or interact with a number of actin-binding proteins.
...
PMID:3-D image reconstruction of reconstituted smooth muscle thin filaments containing calponin: visualization of interactions between F-actin and calponin. 936 53


<< Previous 1 2 3 4 5 6 Next >>

---